NAV

Formebolone

Identification

Generic Name
Formebolone
DrugBank Accession Number
DB01569
Background

Formebolone, a derivative of androstane, is an anabolic androgenic steroid. It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.1 It is also classified by the US Drug Enforcement Administration as Schedule III drug in the Controlled Substances Act. It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.1 Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery.

Type
Small Molecule
Groups
Experimental, Illicit
Structure
3D
Similar Structures
Weight
Average: 344.4446
Monoisotopic: 344.198759384
Chemical Formula
C21H28O4
Synonyms
  • 11-alpha,17-beta-Dihydroxy-17-methyl-3-oxoandrosta-1,4-diene-2-carboxaldehyde
  • 2-Formyl-11-alpha-hydroxy-delta(sup 1)-methyltestosterone
  • 2-formyl-11α-hydroxy-17α-methyl-δ1-testosterone
  • 2-Formyl-17-alpha-methylandrosta-1,4-diene-11-alpha,17-beta-diol-3-one
  • Esiclene
  • Formebolona
  • Formebolone
  • Formebolonum
  • Formyldienolone
External IDs
  • DEA No. 4000
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

No approved indications. Studied experimentally as a treatment for non-pituitary growth retardation.1

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UCorticosteroid 11-beta-dehydrogenase isozyme 2
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbciximabFormebolone may increase the anticoagulant activities of Abciximab.
AcenocoumarolFormebolone may increase the anticoagulant activities of Acenocoumarol.
AlteplaseFormebolone may increase the anticoagulant activities of Alteplase.
AncrodFormebolone may increase the anticoagulant activities of Ancrod.
AnistreplaseFormebolone may increase the anticoagulant activities of Anistreplase.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Esiclene / Hubernol / Metanor

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-alpha-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
11-alpha-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Alcohol / Aldehyde / Aliphatic homopolycyclic compound / Androgen-skeleton / Carbonyl group
show 12 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Z2MMV08KUQ
CAS number
2454-11-7
InChI Key
AMVODTGMYSRMNP-GNIMZFFESA-N
InChI
InChI=1S/C21H28O4/c1-19-9-12(11-22)16(23)8-13(19)4-5-14-15-6-7-21(3,25)20(15,2)10-17(24)18(14)19/h8-9,11,14-15,17-18,24-25H,4-7,10H2,1-3H3/t14-,15-,17+,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,3aS,3bS,9aR,9bS,10R,11aS)-1,10-dihydroxy-1,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-8-carbaldehyde
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C(C=O)=C[C@]12C

References

Synthesis Reference

Canonica, Luigi; Jommi, Giancarlo; Pelizzoni, Francesca; Scolastico, Carlo. 1,11-Oxido steroids. I. 1a,11a-Oxidoandrostanes. Gazzetta Chimica Italiana (1965), 95(3), 138-50.

General References
  1. Cuatrecasas Membrado JM, Bosch Banyeres JM: [Study of non-hypophysiary growth retardation treated with formebolone]. An Esp Pediatr. 1985 Jan;22(1):27-32. [Article]
Human Metabolome Database
HMDB0004631
PubChem Compound
17150
PubChem Substance
46508967
ChemSpider
16234
ChEBI
135456
ChEMBL
CHEMBL2107419
ZINC
ZINC000004216332
Wikipedia
Formebolone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusDiagnosticColorectal Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)210.5 °CPhysProp
boiling point (°C)543.6 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0605 mg/mLALOGPS
logP2.59ALOGPS
logP1.76Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.39Chemaxon
pKa (Strongest Basic)-2.9Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area74.6 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity96.9 m3·mol-1Chemaxon
Polarizability38.13 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9575
Caco-2 permeable+0.6357
P-glycoprotein substrateSubstrate0.7668
P-glycoprotein inhibitor INon-inhibitor0.7709
P-glycoprotein inhibitor IINon-inhibitor0.793
Renal organic cation transporterNon-inhibitor0.8094
CYP450 2C9 substrateNon-substrate0.8477
CYP450 2D6 substrateNon-substrate0.9066
CYP450 3A4 substrateSubstrate0.7647
CYP450 1A2 substrateNon-inhibitor0.8748
CYP450 2C9 inhibitorNon-inhibitor0.8936
CYP450 2D6 inhibitorNon-inhibitor0.9646
CYP450 2C19 inhibitorNon-inhibitor0.9333
CYP450 3A4 inhibitorNon-inhibitor0.8312
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9428
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.9452
BiodegradationNot ready biodegradable0.9741
Rat acute toxicity3.2193 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.925
hERG inhibition (predictor II)Non-inhibitor0.8035
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-00or-1549000000-42102185d1dded40ecea
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-0029000000-90036ceebba4657fa259
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0009000000-62a550570d0ce6c6ccc6
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-4796000000-979db11d3e8ee87a514a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0009000000-a5942976262fb4391c7b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03dj-2689000000-fd4454ebc2e4407b5b1a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0k9j-1940000000-af01d612113a41aca6d3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-190.8718834
predicted
DarkChem Lite v0.1.0
[M-H]-190.1092834
predicted
DarkChem Lite v0.1.0
[M-H]-177.40083
predicted
DeepCCS 1.0 (2019)
[M+H]+190.5565834
predicted
DarkChem Lite v0.1.0
[M+H]+190.8707834
predicted
DarkChem Lite v0.1.0
[M+H]+179.2274
predicted
DeepCCS 1.0 (2019)
[M+Na]+189.5109834
predicted
DarkChem Lite v0.1.0
[M+Na]+190.7059834
predicted
DarkChem Lite v0.1.0
[M+Na]+184.93037
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Corticosteroid 11-beta-dehydrogenase isozyme 2
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
Catalyzes the conversion of cortisol to the inactive metabolite cortisone. Modulates intracellular glucocorticoid levels, thus protecting the nonselective mineralocorticoid receptor from occupation...
Gene Name
HSD11B2
Uniprot ID
P80365
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 2
Molecular Weight
44126.06 Da
References
  1. Furstenberger C, Vuorinen A, Da Cunha T, Kratschmar DV, Saugy M, Schuster D, Odermatt A: The anabolic androgenic steroid fluoxymesterone inhibits 11beta-hydroxysteroid dehydrogenase 2-dependent glucocorticoid inactivation. Toxicol Sci. 2012 Apr;126(2):353-61. doi: 10.1093/toxsci/kfs022. Epub 2012 Jan 23. [Article]

Drug created at July 31, 2007 13:10 / Updated at February 21, 2021 18:51